"Plus, there are possibly more attractive opportunities in other health companies at the moment"
That entirely depends on your sentiment about success with deals, the 2nd read-out and the full trial outcomes.
If they fail, yes, there are many better opportunities. But if they all succeed, you are unlikely to find a better biotech opportunity than this at the moment.
Until things are clearer, the market will ebb and flow with the changing balance between belief and doubt.
Ann: Investor Presentation, page-114
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.035(10.3%) |
Mkt cap ! $206.1M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 37.5¢ | 33.5¢ | $2.127M | 5.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 110810 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 199600 | 5 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.5¢ |
Change
0.035 ( 8.70 %) |
||||
| Open | High | Low | Volume | ||
| 34.5¢ | 37.5¢ | 34.0¢ | 3558922 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| DXB (ASX) Chart |